XiaojinAn Ph.D.

Counsel

Beijing + 86.10.5866.1130 Munich + 49.89.20.60.42.200

Connect:

Share

Xiaojin An focuses her practice on obtaining and defending intellectual property rights for clients in the biotechnology, pharmaceuticals, and diagnostics sectors. She advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and conducts IP due diligence for life science companies and venture capital firms.

Xiaojin has extensive experience in building up and managing patent portfolio from the early stage of drug development through late stage clinical trials and obtaining patent term extensions to maximize the protection of approved drug by regulatory agencies to help clients leverage IP rights in business strategies and transactions.

Xiaojin serves a wide spectrum of clients ranging from small start-ups to multinational pharmaceutical companies particularly in the technical areas including antibodies, peptides, vaccines, stem cells, immune therapies, RNA therapies, diagnostic methods, gene editing, and precision medicine. Representative clients include Celgene Corporation, REGENXBIO, Hookipa Biotech GmbH, Memorial Sloan Kettering Cancer Center, Celularity, Zensun (Shanghai) Sci & Tech Co., and Gmax Biopharm.

Prior to joining Jones Day in 2013, Xiaojin was a postdoctoral fellow at the Swiss Federal Institute of Technology Zurich (ETH), where her research focused on profiling circulating microRNA biomarkers for cancer and identification of metabolic addiction pathways for cancer cell survival. Xiaojin carried out her Ph.D. studies at Harvard Medical School and Peking University. She received an outstanding doctoral dissertation award for her work on angiogenesis in cancer and cardiovascular disease, focusing on gene regulation in hypoxic endothelium. Xiaojin has published eight research articles and reviews in peer-reviewed top journals.

Experience

  • BMS secures EPO precedential victory on epitope claimsJones Day successfully represented licensee Bristol Myers Squibb’s wholly owned subsidiary Celgene Corporation in the defense of European patent EP 2812443 directed to CD47 antibodies defined by a conformational epitope, in opposition proceedings at the European Patent Office, triggering the first decision that acknowledges patentability of conformational epitope claiming in Europe.
  • Hookipa successfully defends its tri-segmented arenavirus platform technology patent in EPO opposition proceedingsJones Day successfully defended Hookipa Biotech GmbH in opposition proceedings at the European Patent Office.
  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
    • View All

    August 2024 Alert

    Epitope Claims Live On at the European Patent Office

    November 2023 Commentary

    The EPO Adopts a Patentee-Friendly Approach on Assessing Formal Priority Entitlement

    August 2015 Commentary

    Partial Priority and Dealing with "Toxic Divisionals" under the European Patent Convention

    Additional Speaking Engagements

    • September 17, 2021
      Patent strategy for Chinese Companies Going Abroad, 6th China Pharma IP Summit
    • October 16, 2020
      Antibody patenting strategy for global protection, 5th China Pharma IP Summit
    • September 25, 2019
      Maximizing protection for your key therapeutic product in Europe.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.